A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to volunteers for the first time. Launched on the 4th of August 2023, the clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination. The study is led by Professor Teresa Lambe, Principal Investigator at the Oxford Vaccine Group (OVG) and Pandemic Sciences Institute (PSI) at the University of Oxford. Katrina Pollock, Clinician Scientist in the Vaccinology Department of Paediatrics, University of Oxford said: 'Here at the Oxford Vaccine Group, we are responding to this public health threat by developing a vaccine to protect against CCHF'. About the StudyThe Oxford Vaccine Group are based at the Centre for Clinical Vaccinology and Tropical Medicine at the Churchill Hospital, where all study visits/appointments will take place.